Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase ...

Vactosertib is under clinical development by MedPacto and currently in Phase I for Metastatic Colorectal Cancer.

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer. IROX does not change ...

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

More information: Thierry Andre et al, Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2402141 ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

or metastatic non–small cell lung cancer (NSCLC) or pancreatic adenocarcinoma harboring a NRG1 gene fusion who had disease progression on or after prior systemic therapy. 1 This is the first FDA ...